NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: LINCOLN · data 2026-11-01
Lincoln Pharmaceuticals Ltd
In plain words
Price: 35.2% below its 52-week high of ₹770.
Delivery: 40.2% of traded shares were kept for delivery over the last 10 sessions, against 50.8% over the last 60.
Latest results: a net profit of ₹20 cr for the quarter ended Sept 2026 (+2.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹694 cr |
| Net profit (last 12 months) | ₹96 cr |
| Sales growth, 3 years (yearly) | 9.4% |
| Profit growth, 3 years (yearly) | 6.4% |
At a glance
Promoters 49.8% (unchanged in a year), pledged 0.0%, institutions 4.6%.
P/E 10.4, dividend yield 0.4%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.3%, ROCE 10.9%, operating margin 12.4%: how much profit it earns on the money it uses.
Debt/equity 0.01, Profit growth 6.4% and sales growth 9.4% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
LINCOLN Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹191.35 crore, up 17.1% YoY and up 7.9% QoQ.
Net profit was ₹20.43 crore, up 2.3% YoY and down 43.6% QoQ.
Operating margin was 12.4% (15.6% a year ago).
EPS was ₹10.2, up 2.2% YoY and down 43.6% QoQ.
LINCOLN के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹191.35 करोड़; पिछले साल की तुलना में 17.1% की बढ़त, पिछली तिमाही की तुलना में 7.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹20.43 करोड़; पिछले साल की तुलना में 2.3% की बढ़त, पिछली तिमाही की तुलना में 43.6% की गिरावट।
ऑपरेटिंग मार्जिन: 12.4% (एक साल पहले 15.6%)।
EPS: ₹10.2; पिछले साल की तुलना में 2.2% की बढ़त, पिछली तिमाही की तुलना में 43.6% की गिरावट।
LINCOLNના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹191.35 કરોડ; ગયા વર્ષની સરખામણીએ 17.1% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 7.9% વધારો.
ચોખ્ખો નફો: ₹20.43 કરોડ; ગયા વર્ષની સરખામણીએ 2.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 43.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 12.4% (એક વર્ષ પહેલાં 15.6%).
EPS: ₹10.2; ગયા વર્ષની સરખામણીએ 2.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 43.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
9/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 4/30: Delivery 36.3% over the last 20 sessions vs 35.4% in the 40 before (1.03x); shares delivered per day 1x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 29 Oct 26Results Q2 FY27 results: profit +2.3% YoY -10.5% next session
- 11 Sept 26Dividend Dividend ₹1.8 (ex-date) -5.0% next session
- 13 Aug 26Results Q1 FY27 results: profit +30.9% YoY +3.5% next session
- 28 May 26Results Q4 FY26 results: profit +0.5% YoY -16.5% next session
- 12 Feb 26Results Q3 FY26 results: profit +37.7% YoY +23.7% next session
- 13 Nov 25Results Q2 FY26 results: profit −24.1% YoY -0.8% next session
- 12 Sept 25Dividend Dividend ₹1.8 (ex-date) -0.9% next session
- 7 Aug 25Results Q1 FY26 results: profit +16.9% YoY +5.9% next session
- 22 May 25Results Q4 FY25 results: profit −37.8% YoY -7.7% next session
- 13 Feb 25Results Q3 FY25 results: profit −25.9% YoY -15.5% next session
- 14 Nov 24Results Q2 FY25 results: profit −4.8% YoY -2.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹191 cr | ₹20 cr | +2.3% | 12.4% | 10.2 |
| Jun 2026 | ₹177 cr | ₹36 cr | +30.9% | 15.5% | 18.09 |
| Mar 2026 | ₹187 cr | ₹12 cr | +0.5% | 13.3% | 5.81 |
| Dec 2025 | ₹166 cr | ₹29 cr | +37.7% | 14.2% | 14.28 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 49.78% | 49.78% | 49.78% | 49.78% |
| Foreign institutions (FII) | 4.55% | 4.60% | 5.19% | 4.70% |
| Domestic institutions (DII) | 0.02% | 0.27% | 1.09% | 0.01% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 24.69% | 24.35% | 23.58% | 25.10% |
| Number of shareholders | 29,272 | 29,396 | 28,303 | 31,026 |
Common questions
What was Lincoln Pharmaceuticals Ltd's latest quarterly profit?
Lincoln Pharmaceuticals Ltd reported a net profit of ₹20 cr for the quarter ended Sept 2026 (+2.3% on the same quarter a year earlier), on revenue of ₹191 cr.
How much do promoters hold in Lincoln Pharmaceuticals Ltd?
Promoters held 49.78% of Lincoln Pharmaceuticals Ltd at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Lincoln Pharmaceuticals Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.01, which is very low.
What is Lincoln Pharmaceuticals Ltd's P/E ratio?
About 10.4, based on the last 12 months' earnings and a price of ₹499.3 (data 2026-11-01).
What is the 52-week high and low of Lincoln Pharmaceuticals Ltd?
The 52-week high is ₹770 and the 52-week low is ₹440.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | ₹499.3 | ₹1,005 cr | 10.4 | — | 12.3% | 10.9% | 0.01 | -5.8% |
| Bafna Pharmaceuticals Limited | ₹447.9 | ₹1,060 cr | 136.1 | — | 12.3% | 9.2% | 0.39 | +218.1% |
| Bajaj Healthcare Ltd | ₹306.3 | ₹1,031 cr | 51.5 | 1.9 | 4.3% | 13.2% | 0.47 | -33.3% |
| Sigachi Industries Limited | ₹26.36 | ₹1,009 cr | 39.7 | — | -14.6% | 6.1% | 0.31 | -29.4% |
| Remus Pharmaceuticals Ltd. | ₹843.35 | ₹994 cr | 26.9 | 2.8 | 12.2% | 14.7% | 0.08 | +27.8% |
| Sudarshan Pharma Industries Ltd | ₹36.42 | ₹895 cr | 31.1 | 4.7 | 16.3% | 28.8% | 1.84 | +7.7% |
Compare LINCOLN with BAFNAPH in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LINCOLN in NSE Scanner →